Consolidated Standards of Reporting Trials diagram. See Table 2 for “intensification” as salvage therapy. AML, acute myeloid leukemia; BSC, best supportive care; CRs, complete responders; HD-MTX, high-dose methotrexate; MATRix, methotrexate, cytarabine, thiotepa, and rituximab; PD, progressive disease; PR, partial responders; RICE, rituximab, ifosfamide, cyclophosphamide, and etoposide; RT, radiation therapy.